Fecal microbiota transplantation for Parkinson's disease: Findings from a clinical trial
New research published in JAMA Neurology finds that fecal microbiota transplantation (FMT) is safe but does not offer clinically meaningful improvements for Parkinson's disease.
Importance
The gut microbiome has emerged as a target for diverse diseases including Parkinson's disease (PD). Dysbiosis has been robustly demonstrated in PD and fecal microbiota transplantation (FMT) has shown promise in animal models of PD.
Objective
To evaluate the safety and efficacy of FMT in patients with PD.
Design
A single-center, double-blind, randomized placebo-controlled trial.
Setting
A movement disorders clinic in an academic medical center.
Participants
Eighty patients with PD
Intervention
Participants were randomized to receive either FMT or placebo.
Comments